Literature DB >> 11840249

Inhaled nitric oxide for oligohydramnios-induced pulmonary hypoplasia: a report of two cases and review of the literature.

Cara Geary1, Jeffrey Whitsett.   

Abstract

We describe the clinical courses of two premature infants, a male born at 29(4/7) weeks' gestational age after an 8-week period of rupture of membranes (ROM) and severe oligohydramnios, and a female infant born at 31 weeks' gestational age after an 18-week period of ROM and severe oligohydramnios. Within hours after birth, despite intubation and aggressive ventilation, both infants developed fulminant hypoxic respiratory failure. Their clinical courses were consistent with pulmonary hypertension and both infants were transferred for trials of inhaled nitric oxide (iNO). Both infants had dramatic responses to iNO, suggesting that the pulmonary disease seen after prolonged oligohydramnios may have a component of nitric oxide-sensitive pulmonary hypertension. The goals of this article are to (1) review oligohydramnios-induced pulmonary hypoplasia, (2) discuss patients at highest mortality risk, and (3) describe the effects of iNO on pulmonary hypertension in infants with hypoxemia following prolonged ROM and severe oligohydramnios.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840249     DOI: 10.1038/sj.jp.7210580

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  14 in total

1.  Prolonged respiratory disorder predicts adverse prognosis in infants with end-stage kidney disease.

Authors:  Tomoyuki Sakai; Yoshitaka Murakami; Yusuke Okuda; Riku Hamada; Yuko Hamasaki; Kenji Ishikura; Hiroshi Hataya; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2016-06-07       Impact factor: 3.714

2.  Inhaled nitric oxide in preterm infants with prolonged preterm rupture of the membranes: a case series.

Authors:  J Semberova; S M O'Donnell; J Franta; J Miletin
Journal:  J Perinatol       Date:  2015-04       Impact factor: 2.521

Review 3.  Inhaled nitric oxide therapy for pulmonary disorders of the term and preterm infant.

Authors:  Gregory M Sokol; Girija G Konduri; Krisa P Van Meurs
Journal:  Semin Perinatol       Date:  2016-10       Impact factor: 3.300

4.  Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia.

Authors:  Kevin R Ellsworth; Marc A Ellsworth; Amy L Weaver; Kristin C Mara; Reese H Clark; William A Carey
Journal:  JAMA Pediatr       Date:  2018-07-02       Impact factor: 16.193

5.  Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series.

Authors:  A T James; C Bee; J D Corcoran; P J McNamara; O Franklin; A F El-Khuffash
Journal:  J Perinatol       Date:  2014-11-27       Impact factor: 2.521

6.  Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use.

Authors:  Maurizio Radicioni; Alessia Bruni; Piergiorgio Camerini
Journal:  Eur J Pediatr       Date:  2011-03-08       Impact factor: 3.183

7.  Early Use of Inhaled Nitric Oxide in Preterm Infants: Is there a Rationale for Selective Approach?

Authors:  Praveen Chandrasekharan; Rafal Kozielski; Vasantha H S Kumar; Munmun Rawat; Veena Manja; Changxing Ma; Satyan Lakshminrusimha
Journal:  Am J Perinatol       Date:  2016-09-14       Impact factor: 1.862

Review 8.  Management of hypoxemic respiratory failure and pulmonary hypertension in preterm infants.

Authors:  N Ambalavanan; J L Aschner
Journal:  J Perinatol       Date:  2016-06       Impact factor: 2.521

9.  Nitric oxide in preterm infant with pulmonary hypoplasia.

Authors:  Nandkishor S Kabra; Martin R Kluckow; Jane Powell
Journal:  Indian J Pediatr       Date:  2004-05       Impact factor: 1.967

10.  Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia.

Authors:  Valerie Y Chock; Krisa P Van Meurs; Susan R Hintz; Richard A Ehrenkranz; James A Lemons; Douglas E Kendrick; David K Stevenson
Journal:  Am J Perinatol       Date:  2008-12-09       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.